Immuneering (IMRX) Other Non Operating Income (2021 - 2026)

Immuneering (IMRX) posted quarterly Other Non Operating Income of $513735.0 for Q1 2026, up 64.84% quarter-over-quarter from $311665.0 in Q4 2025.

Immuneering (IMRX) Other Non Operating Income (2021 - 2026) Analysis & Trends

Immuneering's Other Non Operating Income history runs 6 years deep, the most recent figure standing at $513735.0 for Q1 2026.

In Q1 2026, Other Non Operating Income changed N/A year-over-year to $513735.0; the TTM figure through Mar 2026 stood at $825400.0 (up 261.29% YoY), while the FY2025 annual figure was $311665.0, down 29.41% from the prior year.
Other Non Operating Income for Q1 2026 stood at $513735.0, up from $311665.0 in the prior quarter.
The five-year high for Other Non Operating Income was $513735.0 in Q1 2026, with the low at -$103218.0 in Q1 2022.
The 5-year median for Other Non Operating Income is $181615.0 (2023), against an average of $201286.1.
The sharpest annual moves came in 2022 and 2024: Other Non Operating Income jumped 1593.82% in 2022, then sank 94.86% in 2024.
Immuneering's Other Non Operating Income stood at $223278.0 in 2022, then jumped by 107.97% to $464352.0 in 2023, then tumbled by 80.31% to $91430.0 in 2024, then surged by 240.88% to $311665.0 in 2025, then soared by 64.84% to $513735.0 in 2026.
Business Quant data shows IMRX's Other Non Operating Income at $513735.0 in Q1 2026, $311665.0 in Q4 2025, and $91430.0 in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Immuneering	327.37 Mn	327.37 Mn	-

Download Data